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Abstract 
  
 The molecular alterations that occur in cells before cancer is manifest are largely 
uncharted. Lung carcinoma-in-situ (CIS) lesions are the pre-invasive precursor to squamous 
cell carcinoma. While microscopically identical, their future is in equipoise with half 
progressing to invasive cancer and half regressing or remaining static. The cellular basis of 
this clinical observation is unknown. Here, we profile the genomic, transcriptomic and 
epigenomic landscape of CIS in a unique patient cohort with longitudinally monitored pre-
invasive disease. Predictive modelling identifies which lesions will progress with remarkable 
accuracy. We identify progression-specific methylation changes on a background of 
widespread heterogeneity, alongside a strong chromosomal instability signature. We observe 
mutations and copy number changes characteristic of cancer and chart their emergence, 
offering a window into early carcinogenesis. We anticipate this new understanding of cancer 
precursor biology will improve early detection, reduce over-treatment and foster preventative 
therapies targeting early clonal events in lung cancer. 
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Introduction  
 
 Lung cancer is the commonest cause of cancer death worldwide with 1.5 million deaths 
per year1. Lung squamous cell carcinoma (LUSC) is the most common subtype in parts of 
Europe and second in the U.S.A.2 Before progression to invasive LUSC, there is step-wise 
evolution of ever more disordered pre-invasive lesions, ranging from mild and moderate 
dysplasia (low-grade lesions) to severe dysplasia and carcinoma-in-situ (CIS; high-grade 
lesions).3 The accessibility of the proximal airways allows detection and monitoring of these 
lesions using high-resolution diagnostic approaches such as autofluorescence bronchoscopy 
(AFB)4. This technique enables the acquisition of tissue throughout the natural history of 
LUSC, providing an excellent model to study early tumorigenesis in human patients. 
 Clinically, the optimal management of pre-invasive airway lesions remains unclear, 
despite the availability of surgery, radiotherapy and ablative techniques5. AFB with biopsy 
allows assessment of the size, gross morphology and histopathology of pre-invasive lesions 
(Fig. 1a, b) but cannot distinguish lesions that will ultimately progress to invasive tumours from 
those that will spontaneously regress. As such, indiscriminate surgical resection of pre-
invasive lesions or external beam radiotherapy probably represent over-treatment: lesions will 
spontaneously regress in 30% of cases, patient co-morbidity and poor lung function impart 
considerable risk, and the presence of field cancerization means independent lung cancers 
frequently emerge at sites outside resection or therapy margins.6 
 We reasoned that information on the future clinical trajectory of a pre-invasive lung lesion 
might be encoded in the genetic and epigenetic profile present at diagnosis. We therefore 
undertook a prospective cohort study of patients with pre-invasive squamous airway lesions. 
Patients were managed conservatively, undergoing surveillance AFB with biopsy and CT 
scanning every 4 and 12 months, respectively, with definitive cancer treatment only performed 
at the earliest pathological evidence of progression to invasive tumours (Fig. 1a, b).7 When a 
CIS lesion either progressed to invasive cancer or regressed to normal epithelium/low-grade 
disease, molecular profiling was performed on the preceding CIS biopsy from the same lesion 
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– the ‘index biopsy’ (Fig. 1c). Index biopsies all demonstrated histologically and 
morphologically indistinguishable CIS and were classified as either ‘progressive’ or 
‘regressive’. All such index CIS biopsies were subjected to a predetermined combination of 
transcriptomic, epigenetic and finally genomic profiling depending on DNA/RNA availability 
(Fig. 1d; Table 1; Extended Data Fig. 1; Supplementary Table 1). 
 Whilst molecular techniques have revolutionized our understanding of cancer biology, 
the key steps from normal cell to the point of cancer (uncontrolled growth and invasion) remain 
unclear. This is, to our knowledge, a unique collection of high-grade pre-invasive lung lesions 
for which prospective follow-up under conservative management enabled their natural history 
to declare.  
 
Results 
 
Patient Characteristics 
 
Patients with pre-invasive lung cancer lesions were recruited through University College 
London Hospitals (UCLH) Early Lung Cancer Surveillance Programme (ELCSP). Full details 
of the surveillance protocol including eligibility criteria for patient inclusion have been 
previously described7. Briefly, the programme has recruited 140 patients to date with pre-
invasive lung cancer lesions of varying histological grades. 129 index CIS biopsies were 
obtained from 85 patients and subjected to molecular analysis (Supplementary Table 1). 
Dependent on stored tissue quantity, in total, 51 samples from 42 patients underwent gene 
expression profiling; 87 samples from 47 patients underwent methylation profiling; and 39 
samples from 29 patients underwent whole genome sequencing. Methylation and gene 
expression datasets were divided into independent discovery and validation groups. 
 Clinical characteristics within each analysis group are shown in Table 1. In comparing 
progressive and regressive samples, we found that progressive samples were associated with 
a higher pack-year smoking history in the methylation discovery group only (p < 0.01) and with 
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increased age in the WGS group (p = 0.01). No clinical differences were consistently observed 
across the different analysis groups.  
 
Characterization of CIS genomic profiles 
We believe that the 39 CIS lesions are the first pre-invasive LUSC lesions to be whole-
genome sequenced, so we compared the burden and spectrum of mutations in CIS with 
publicly available LUSC exome sequencing data from The Cancer Genome Atlas (TCGA). 
Due to differences between whole-genome and exome sequencing, only broad comparisons 
can be made. We observe a similar mutation burden and copy number profile between CIS 
samples and TCGA LUSC tumours (Fig. 2). There is congruency of type and prevalence of 
potential driver mutations, broadly defined as any mutation in a gene previously implicated as 
a driver of lung cancer, between CIS and LUSC samples8. We observe frequent alterations in 
TP53, CDKN2A, SOX2 and AKT2, and less frequent alterations in FAT1, KMT2D, KEAP1, 
EGFR and NOTCH1 in CIS lesions (Fig. 2; Supplementary Table 2). CIS mutational 
signatures9,10 showed a strong tobacco-associated signal and were similar to those found in 
LUSC (Extended Data Fig. 2). 
Marked aneuploidy was observed in CIS lesions, with somatic copy number alterations 
(CNAs) present across the genome (Fig. 2; Extended Data Fig. 3). The most frequent 
changes were associated with gain and amplification of multiple locations on distal 3q: this is 
known to be the most common genomic aberration in LUSC11. Other recognised copy number 
associations identified in our data include gain/amplification in 5p, 8q and 19q and regions of 
loss/deletion in 3p, 4q, 5q, 8p, 9p and 13q.12-18 
Whilst most CIS samples have the genomic appearance of neoplasms, we observe six 
lesions which show markedly lower mutational load and fewer copy number alterations than 
the others (Extended Data Fig. 3; PD21884c, PD21885a, PD21885c, PD21904d, PD38317a, 
PD38319a). These samples have very few genomic changes, despite being CIS histologically. 
All of these six samples regressed to normal epithelium or low-grade dysplasia on subsequent 
biopsy. Four further samples met this end-point for regression, despite widespread mutational 
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and copy number changes. However, with longer follow up one of these cases developed CIS 
recurrence (Extended Data Fig. 4a; PD21893a), and two developed invasive cancer on 
further surveillance (Extended Data Fig. 4b,c; PD21884a, PD38326a). Only one sample, 
PD21908a, showed sustained clinical regression after 9 years of follow up despite widespread 
molecular changes. 
All but one progressive sample and all highly mutated regressive samples showed 
amplification in a small region of distal 3q (chr3:172516434-178440382). This region contains 
the gene ECT2, a regulator of cytokinesis which is associated with chromosomal instability. 
Progressive sample PD38320a had little change outside this region and did not harbour a 
TP53 mutation, suggesting that this amplification may be a crucial early event in LUSC 
tumorigenesis. 
We compared genomic features between the 29 progressive and 10 regressive 
lesions. The three samples which showed evidence of progression after meeting our end-point 
for regression were excluded from this analysis. Comparisons of mutation burden between 
progressive and regressive lesions were performed by mixed effects modelling, allowing us to 
account for samples that come from the same patient. Even after correcting for patient age, 
smoking history and sample purity, progressive lesions had more somatically acquired 
mutations than those from regressive lesions, across base substitutions (p<0.001), indels 
(p=0.018), structural variants (p<0.001) and copy number changes (p<0.001) (Extended Data 
Fig. 5a-d). When the analysis was restricted only to substitutions that were fully clonal in each 
lesion, there were still substantially more substitutions in progressive than regressive lesions 
(p<0.001) (Extended Data Fig. 5e), suggesting that the increase in mutation burden is not 
due to recent subclonal diversification in progressive lesions. All the mutational processes (or 
signatures9,10) identified in the CIS lesions contribute to the excess of mutations in progressive 
compared to regressive samples; however, only tobacco-associated signature 4 showed 
proportionally more mutations (p=0.017) (Extended Data Fig. 2f-j). Progressive lesions 
contained more putative driver mutations than regressive lesions (p=0.001) (Extended Data 
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Fig. 5h; Supplementary Table 2). Importantly, no single cancer mutation perfectly 
discriminated between progressive and regressive lesions.  
Within the biopsied lesions, clonal architecture was similar between progressive and 
regressive lesions (Extended Data Fig. 5e-g). For four patients in whom we sequenced 
multiple progressive lesions, the lesions shared many somatic mutations despite their different 
locality in the bronchial tree, indicating their probable derivation from a common ancestral 
clone. By contrast, multiple regressive lesions from two further patients did not share common 
mutations and so are likely to have arisen independently (Extended Data Fig. 6). There were 
no differences in telomere lengths between progressive and regressive lesions (p=0.59) 
(Extended Data Fig. 5i). 
 
CIS transcriptomic and epigenetic profiles 
Gene expression microarrays were performed on a discovery set of 17 progressive 
and 16 regressive CIS lesions. We identified 1335 genes with significant expression changes 
(FDR < 0.01); 657 genes were up-regulated and 678 down-regulated in progressive CIS 
lesions (Fig. 3a and Supplementary Table 3). 
Differential analysis of methylation profiles was performed on a discovery set of 26 
progressive, 11 regressive and 23 control samples. Widespread methylation changes were 
observed with 12,064 differentially methylated positions (DMPs), associated with 2,695 genes, 
at which methylation was significantly different between progressive and regressive samples 
(FDR < 0.01; || > 0.3). 6,314 DMPs were hypermethylated and 5,750 hypomethylated in 
progressive CIS (Fig. 3b and Supplementary Table 3). 260 differentially methylated regions 
(DMRs) were identified, of which 151 (58%) overlap with DMRs between TCGA cancer and 
control data (Extended Data Fig. 7). Finally, we identified 36,620 differentially variable 
positions (DVPs) for which probe variance was markedly different between progressive and 
regressive groups.  
Of the 1335 genes identified, TPM3, PTPRB, SLC34A2, KEAP1, NKX2-1, SMAD4 and 
SMARCA4 have previously been implicated as potential lung cancer drivers (Supplementary 
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Table 4). Regarding methylation, the potential driver genes NKX2-1, TERT, DDR2, LRIG3, 
CUX1, EPHA3, CSMD3, MET, ZNF479, GRIN2A, PTPRD, NOTCH1, CD74, NSD1 and 
CDKN2A contain at least one significant DMP. Several genes which are significant in our gene 
expression analysis are also identified in our methylation data, including multiple genes in the 
homeobox family (HOXC8, HOXC9, HOXC10, HOXD10, HOXA11AS), previously implicated 
as an early epigenetic event in multiple cancers19. NKX2-1 (TTF-1) is the only putative driver 
gene to be identified in both gene expression and methylation analyses, and is also a member 
of the homeobox family. It is hypermethylated and underexpressed in progressive samples 
compared to regressive. This gene is widely used in diagnosis of lung adenocarcinoma and 
both underexpression and hypermethylation have been implicated in the development of this 
disease20,21. NKX2-1 loss has been shown to drive squamous cancer formation in combination 
with SOX2 overexpression22; focal gains in the 3q region containing SOX2 are commonly 
observed in progressive CIS (Extended Data Fig. 4). 
Principal component analysis of all gene expression and methylation data showed a 
clear distinction between the progressive and regressive subgroups (p=0.0017 and p=6.8x10-
25, respectively) (Fig. 3c,d). In the methylation dataset, the regressive lesions closely clustered 
with the control normal epithelial cells. A history of chronic obstructive pulmonary disease 
(COPD) had an effect on case segregation (p=1.2x10-5) but all other clinical and technical 
variables analysed, including smoking status and history of lung cancer, had no effect 
(Extended Data Fig. 8a-f). This was also the case for PCA analysis of the gene expression 
data (Extended Data Fig. 8g-k). 
For methylation, one control and four regressive cases clustered with the progressive 
cases (Fig. 3d). Three of the four mis-classified regressive cases were subjected to whole-
genome sequencing and were found to have more copy number alterations than other 
regressive samples (PD21884a, PD21893a, PD21908a). Two of these correspond to the 
samples discussed above, which showed signs of progression after meeting the clinical end 
point of regression (Extended Data Fig. 4). For the control bronchial epithelium sample that 
was classified with the progressive lesions, CIS was detected in a biopsy specimen 12 months 
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later from the same site. Thus, although we have formally treated these cases as mis-
classifications, it is likely that the molecular data underpinning the apparent errors indicate a 
cellular phenotype that is not consistent with a straightforward regressive lesion. 
 
 
Molecular signatures predict CIS outcome  
The ability to predict if a pre-invasive lesion will progress to cancer has important 
clinical implications. For gene expression, we used the above pre-defined discovery set to 
define our classifier (n=33; 17 progressive, 16 regressive; 10-fold cross-validation applied). 
This was applied to a separate validation set (n=18; 10 progressive, 8 regressive). All samples 
in the validation set were classified correctly. When applied to external data from TCGA 
(n=551: 502 LUSC, 49 control), our 291-gene model was able to classify LUSC vs control 
samples with AUC=0.81 (Fig. 4a-c; Extended Data Fig. 9).  
An analogous analysis was performed for methylation using a discovery set of 60 
samples and a validation set of 27 samples. This classified validation samples with AUC=0.99 
and classified external TCGA samples (n=412: 370 LUSC, 42 controls) into LUSC vs controls 
with AUC=0.99, based on a 141-DMP classifier (Extended Data Fig. 10a-i).  
We observed an increased number of methylation probes with intermediate 
methylation in TCGA LUSC cancer vs TCGA control samples (Fig. 4d), reflecting methylation 
heterogeneity in these samples. We therefore developed a methylation heterogeneity index 
(MHI), defined as the number of probes per sample with tlo < ß < thi. Optimization based on 
our discovery set of 26 progressive and 11 regressive samples defined values of tlo = 0.26 and 
thi = 0.88. Control samples were not used in this analysis. This model classified progressive 
vs regressive CIS samples in our validation set with AUC=0.74 and TCGA LUSC vs TCGA 
control samples with AUC=0.96 (Fig. 4e; Extended Data Fig. 10j-n). Multivariate logistic 
regression in our CIS cohort demonstrated that this index was a predictor of progression status 
(p=0.017); previous history of lung cancer was also significantly associated (p=0.02), whereas 
smoking status, COPD status, age and gender were not. 
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Given the widespread nature of methylation changes, we hypothesised that this 
increase in heterogeneity may be a genome-wide process rather than specific to functional 
pathways. To test this theory, we assessed the predictive value of MHI calculated from a 
sample of 2,000 probes, randomly selected from across the genome. Running 10,000 
simulations with each using a different random sample of 2,000 probes gave a mean AUC for 
TCGA LUSC vs TCGA control of 0.95 (95% CI 0.92-0.98) (Fig. 4f), and for progressive vs 
regressive CIS of 0.75 (95% CI 0.69-0.82) (Extended Data Fig. 10n). These results are 
similar to those obtained using the entire set of 450,000 probes, suggesting that methylation 
heterogeneity is a genome-wide process. However, these AUC values are lower than those 
obtained from our predictive model based on just 141 differentially methylated positions, 
suggesting that specific methylation changes are also important, on this background of 
generalised change. 
To build a predictive classifier based on copy number, we used copy number derived 
from methylation data to increase sample size and classified 46 of 54 samples correctly 
(Extended Data Fig. 9g-i). The 154 predictive cytogenetic bands that we identified overlap 
with, but are not limited to, a model previously proposed by van Boerdonk et al.. Our model 
replicated their results, classifying 24/24 regressive samples and 9/12 progressive samples 
correctly23 (Extended Data Fig. 9j-l). When applied to external data from TCGA (n=763: 524 
LUSC, 239 control), our model was able to classify LUSC vs control samples with AUC=0.98 
(Extended Data Fig. 9m-o). 
 We performed further analyses using only one sample per patient to demonstrate that 
our results are not dependent on multiple sampling. The first available sample for each patient 
was selected, with CIS samples prioritized over control samples for methylation data. Results 
are similar to our analysis above, validating our initial results (data not shown). 
 Although we cannot fully exclude that lesions meeting our end point for regression will 
progress in future, most patients in this cohort now have several years of follow up. Of 35 
regressive lesions undergoing molecular profiling (Supplementary Table 1), mean follow up 
was 67 months (median 57 months, range 11-150 months).  
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CIN is an early marker of progression to cancer 
To investigate possible drivers of tumorigenic progression, we performed a differential 
analysis of gene expression data between the progressive and regressive groups. 5 of the top 
100 genes identified have been previously associated with chromosomal instability (CIN)24, as 
defined by the previously published CIN70 signature25 (ACTL6A, ELAVL1, MAD2L1, NEK2, 
OIP5). All five are up-regulated in progressive compared with regressive samples. CIN-related 
genes can predict progression (Fig. 5a); NEK2 expression alone predicts progression with 
AUC=0.93 (Fig. 5b). 
Pathway analysis was performed using the gage Bioconductor package26 to compare 
our differentially expressed genes to KEGG gene sets. The CIN70 gene set was the most 
significant gene set identified (adjusted p value 8.9x10-32; up-regulated in progressive group), 
suggesting a role in early tumorigenesis. Cell cycle and DNA repair pathways were also 
implicated (Fig. 5c; Supplementary Table 5). Results were similar when cell-cycle 
associated genes were removed from the CIN70 signature, suggesting that this is a genuine 
CIN signal rather than a marker of proliferation. 
Performing similar differential analysis of differentially methylated probes found 
widespread changes. The top probes identified were associated with cancer-associated cell 
signalling pathways, including TGF-beta, WNT and Hedgehog, as well as cell cycle and CIN-
associated genes (Fig 5d).  
This CIN signal is consistent with the observed pattern of widespread copy number 
change (Fig. 2). Overall copy number variation for a sample, as measured by Weighted 
Genome Integrity Index (wGII)27, correlates with mean CIN-associated gene expression of that 
sample (Pearson r2=0.473) (Extended Data Fig. 5j). We also observe a correlation between 
local copy number of a gene and expression of that gene, consistent with previous results28,29.  
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Discussion 
In summary, we have delineated changes in the genomic architecture, genome-wide 
gene expression and DNA methylation of pre-invasive cancers with known histological 
evidence of subsequent disease progression or regression. The CIS genome shares many of 
the hallmarks of advanced, invasive LUSC but marked genomic, transcriptomic and epigenetic 
differences exist between lesions that are benign and those that will progress to cancer. Our 
data demonstrate the potential use of these differences in predicting outcome over current 
clinical practice.  
Among the strongest pathways associated with progression is chromosomal instability, 
defined as a high rate of gain or loss of whole (or parts of) chromosomes. CIN is implicated in 
many human cancers, including lung, and has been suggested both as a prognostic marker 
and therapeutic target30,31. Regressive lesions do not have the wholesale genomic instability 
of those that will progress and their epigenetic and transcriptional profiles more closely 
resemble normal bronchial epithelium than invasive cancers. Despite this, CIS lesions that 
spontaneously regress are genuine neoplasms; they harbour many somatic mutations, which 
can include known potential driver mutations. The mechanism of regression remains 
mysterious: it is unclear whether clones become exhausted and die out, potentially abetted by 
immune surveillance, or whether clones persist but phenotypically revert to an architecturally 
normal, physiological epithelium. Likewise the mechanisms of CIN are not well understood; 
our study paves the way for investigation of these CIN-associated genes in model systems to 
elucidate their role. 
We present here the first major whole genome sequencing data of pre-invasive lung 
lesions. We acknowledge that, despite using the world’s largest cohort of such lesions, the 
study remains underpowered to detect less common genomic alterations. Expanding our 
knowledge in this area will require a major international collaboration. Likewise we 
acknowledge that whilst our predictive signatures demonstrate the power of molecular data in 
guiding management decisions, a prospective clinical trial using predictors derived from our 
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data will be required before clinical use. Again, international collaboration will be required to 
develop an appropriately powered trial. 
Despite these limitations, our data offer the first insight into the molecular map of early 
lung squamous cancer pathogenesis, foretelling an era in which molecular profiling will enable 
personally tailored therapeutic decisions for patients with pre-invasive lung disease. 
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Figure Legends 
 
Figure 1. Analysis of pre-invasive lung carcinoma-in-situ (CIS) lesions.  
(a) Detection of bronchial pre-invasive CIS lesions by autofluorescence bronchoscopy. (b) 
Histological outcomes of bronchial pre-invasive lesions. (c) Overview of the study protocol. 
Patients with identified CIS lesions underwent repeat bronchoscopy and rebiopsy every 4 
months. Definitive cancer treatment was only performed if pathological evidence of 
progression to invasive cancer was detected. The ‘index biopsy’ profiled in this study refers to 
the biopsy immediately preceding progression to invasive cancer or regression to low-grade 
dysplasia or normal epithelium. (d) Venn diagram of different -omics analyses performed on 
laser capture microdissection (LCM)-captured CIS lesions. Due to the small size of bronchial 
biopsies, not all analyses were performed on all samples 
 
Figure 2. Genomic aberrations in pre-invasive lung carcinoma-in-situ (CIS) lesions. 
Circos diagram comparing CIS genomic profiles with TCGA LUSC data. The outer histogram 
(A), shows mutation frequencies of all genes in TCGA data. The inner histogram (D) shows 
mutation frequencies in our CIS data. Profiles appear similar and no statistically significant 
differences were identified between the two datasets. Genes previously identified as potential 
drivers of lung cancer are labelled. Between the two histograms, average copy number 
changes are shown for TCGA data (B) and CIS data (C). Copy number gains are shown in 
red, losses in blue. Although differences between whole-genome and whole-exome 
sequencing techniques makes these datasets difficult to compare, we observe many similar 
features between the two; for example, gains in 3q and 5p, which are well recognised features 
of squamous cell lung cancer. In the centre of the circos plot, 39 rings represent the copy 
number profiles of our 39 samples, illustrating the individual contribution of each sample to the 
average values presented (E).  
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Figure 3. Altered methylation and gene expression in lung carcinoma-in-situ (CIS) 
lesions. 
(a) Hierarchical clustering of 1335 significantly differentially expressed genes in progressive 
(n=17) and regressive (n=16) CIS lesions, based on a discovery set. Biological and clinical 
factors including age at diagnosis, gender, smoking history (pack years) and COPD status 
had no effect on CIS lesion gene expression profile (high expression = purple, low expression 
= orange). (b) Hierarchical clustering of the top 1000 significantly differentially methylated 
positions (DMPs) between progressive (n=36) and regressive (n=18) CIS lesions and controls 
(n=33). Biological and clinical factors including age at diagnosis, gender and smoking history 
(pack years) status had no effect on the methylation profile (hypomethylated DMPs = blue, 
hypermethylated DMPs = orange). (c) Principle component analysis of all profiled genes in 
progressive (n=27) and regressive (n=24) CIS lesions showing a clear distinction between 
progressive and regressive groups (p=0.0017). (d) Principle component analysis of all 
methylation data in progressive (n=36), regressive (n=18) and control (n=33) CIS lesions 
showing a clear distinction between progressive and regressive groups (p=6.8x10-25). P values 
were calculated using multivariate ANOVA. 
 
Figure 4. Carcinoma-in-situ (CIS) gene expression and methylation profiles are 
predictive of progression to cancer.  
(a) Probability plot based on a 291-gene signature for correct class prediction (discovery set - 
red circles indicate progressive lesions, green circles indicate regressive lesions). (b) 
Challenging the 291-gene signature on a CIS validation set. Area under the curve (AUC) is 1 
using Receiver Operating Characteristic (ROC) analysis. (c) Application of the 291-gene 
signature to TCGA LUSC data. Our signature classified TCGA LUSC vs TCGA controls 
samples with AUC of 0.81 (green circles indicate TCGA controls, orange circles indicate 
TCGA LUSC). (d) Distribution of methylation beta values across the genome in TCGA 
controls, CIS regressive and progressive and TCGA LUSC samples. Most probes are 
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regulated at 0 or 1 in normal tissue but this regulation is reduced in both regressive and 
progressive CIS and TCGA LUSC samples. (e) Methylation Heterogeneity Index, defined as 
counts of methylation probes with 0.26 < ß < 0.88, for each sample. MHI is higher in regressive 
and progressive CIS and TCGA LUSC compared with TCGA controls and this can be used as 
an accurate predictor with AUC=0.96 for TCGA LUSC vs TCGA controls and AUC=0.74 for 
progressive vs regressive CIS. (f) Histogram of AUC values calculated by performing the same 
analysis used in (e) 10,000 times, with each run limited to a different random sample of 2,000 
probes (AUC mean for TCGA LUSC vs TCGA controls is 0.95 (95% CI 0.92−0.98)). This 
demonstrates that a random sample of methylation probes can be an accurate predictor using 
this method. 
 
Figure 5. Chromosomal instability is associated with progression to cancer. 
(a) Mean expression of CIN-associated genes in CIS samples. Progressive (n=27) and 
regressive (n=24) CIS samples are well differentiated with AUC=0.96. Green circles indicate 
regressive CIS lesions; red circles indicate progressive CIS. (b) Plot of NEK2 expression 
across CIS samples demonstrates increasing expression with progression to cancer. 
Expression of this gene alone classifies progressive vs regressive CIS with AUC=0.93. (c) 
Pathway analysis of gene expression data between progressive (n=17) and regressive (n=16) 
CIS shows a strong chromosomal instability (CIN) signal, based on a discovery set. This signal 
remains strong when cell cycle genes are removed from the CIN70 signature. (d) Pathway 
analysis of methylation data demonstrating several cancer-related pathways up-regulated in 
progressive CIS compared with regressive CIS. Quoted significance values in (c) and (d) are 
calculated using 2-sided t-tests adjusted for multiple testing using a False Discovery Rate 
method, as implemented in the GAGE Bioconductor package.  
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Patients 21 8 13 7 16 9 7 8 16 14 9 8 
Lesions Profiled 29 10 26 11 23 10 7 10 17 16 10 8 
Gender                         
Male 18 8 11 7 15 7 7 7 14 10 7 4 
Female 3 0 2 0 1 2 0 1 2 4 2 4 
Age at 
bronchoscopy 
(years)                         
Mean 71.1 63.1 69.81 63.27 65.96 70.2 69.86 64.3 69.29 66.56 69.4 68.125 
Median 72 65.5 70 67 68 73 68 63 70 67.5 71.5 68 
Range 
58-
81 52-71 52-79 53-79 44-77 58-78 64-76 56-77 55-80 53-81 56-82 57-84 
Smoking 
History (pack 
years)                         
Mean 54.4 54.9 58.08 31 41.95 57.3 62.14 37.71 57.07 47 49.125 59.2 
Median 50 50 59.5 29 40 60 50 36 50 47.5 47.5 58 
Range 
30-
100 9-141 32-141 5-88 20-65 40-75 30-141 20-60 22-141 5-141 30-75 30-96 
COPD status                         
Yes 12 3 9 3 14 5 1 7 4 8 3 7 
No 9 5 4 4 1 4 6 1 12 6 1 0 
Previous 
History of Lung 
Cancer                         
Yes 12 2 6 2 9 7 4 3 5 4 3 4 
No 9 6 7 5 7 2 3 5 11 10 6 4 
 
Table 1. Demographic and clinical characteristics. 
Table showing demographic and clinical characteristics of patients in the whole-genome 
sequencing, methylation discovery and validation, and gene expression discovery and 
validation datasets. 
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Methods 
 
Ethical approval 
 All tissue and bronchial brushing samples were obtained under written informed patient 
consent and were fully anonymised. Study approval was provided by the UCL/UCLH Local 
Ethics Committee (REC references 06/Q0505/12 and 01/0148). All relevant ethical regulations 
were followed. 
 
Code availability 
 
All code used in our analysis will be made available at http://github.com/ucl-
respiratory/preinvasive on publication. All software dependencies, full version information, and 
parameters used in our analysis can be found here.  
 Unless otherwise specified, all analyses were performed in an R statistical environment 
(v3.5.0; www.r-project.org/) using Bioconductor1 version 3.7. 
 
Biological samples 
 All patients with pre-invasive lung cancer lesions were recruited through University 
College London Hospitals (UCLH) Early Lung Cancer Surveillance Programme (ELCSP). Full 
details of the surveillance protocol including eligibility criteria for patient inclusion have been 
previously described.2 Briefly, the programme has recruited 140 patients to date with pre-
invasive lung cancer lesions of varying histological grades. Patients undergo autofluorescence 
bronchoscopy (AFB) and CT/PET scans every four to six months during which multiple biopsy 
specimens are collected. This longitudinal sequential AFB procedure provides biopsies of the 
same lesion sampled repeatedly over time, allowing us to monitor whether the individual 
lesions have progressed, regressed or remained static2.  
 For a given CIS lesion under surveillance, when a biopsy from the same site showed 
evidence of progression to invasive cancer or regression to normal epithelium or low-grade 
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dysplasia, we define the preceding CIS biopsy as the ‘index’ lesion. An index lesion was 
defined as progressive if the subsequent biopsy at the same site showed invasive cancer, or 
as regressive if the subsequent biopsy showed normal epithelium or low-grade disease 
(metaplasia, mild or moderate dysplasia). Lesions which do not satisfy one of these end-points 
were excluded from this study. Patients with multiple fresh-frozen (FF) and formalin-fixed, 
paraffin-embedded (FFPE) tissue biopsies were identified for DNA methylation and gene 
expression analysis, respectively. Laser-capture micro-dissection (LCM) was used to 
selectively isolate CIS cells for molecular analysis, reducing the extent of contamination by 
stromal cells.  
 The following protocol was used to determine which profiling methods were applied to a 
given CIS lesion during our initial data collection phase: 
 If FFPE samples were available, gene expression profiling was performed. For the first 
33 samples (17 progressive and 16 regressive), gene expression profiles were 
generated using Illumina microarrays. Our predictive models are trained on this 
discovery set. Subsequently, a further set of 10 progressive and 8 regressive samples 
from 18 patients were profiled using a different microarray platform (Affymetrix) to 
validate our findings on an independent platform. 
 If FF samples were available, DNA from these samples was first used for methylation 
profiling. Samples with sufficient DNA after DNA profiling were additionally subjected 
to whole-genome sequencing. After acquisition of sufficient samples for our 
methylation dataset (54 samples; 36 progressive, 18 regressive), only 29 samples had 
sufficient DNA for WGS, therefore we prioritised WGS over methylation for the 
subsequent 10 samples. 
 
Tissue processing and laser-capture micro-dissection 
 FF or FFPE tissue sections (7-10μM thickness) were mounted on a MembraneSlide 1.0 
PEN. Prior to cryosectioning, the slides were heat-treated for 4 h at 180°C in a drying cabinet 
to inactivate nucleases. To overcome the membrane’s hydrophobic nature and to allow better 
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section adherence, the slides were then UV-treated for 30 min at 254nm. Prior to laser-capture 
micro-dissection (LCM), the slides containing the FF tissue sections for DNA extraction were 
washed in serial ethanol dilutions (50, 75, 100%) to remove the freezing medium (OCT) and 
to avoid any interference with the laser’s efficiency. For RNA extraction, FFPE sections were 
dewaxed using the Arcturus® Paradise® PLUS Reagent System (Applied Biosystems, Foster 
City, CA, USA). For each case, epithelial areas of pre-invasive disease were identified by 
haematoxylin and eosin staining of the corresponding cryosection (~7 μM thick). The presence 
of epithelial areas of interest was confirmed by histological assessment of each case by two 
histopathologists. LCM to isolate the tissue area/cells of interest was performed with the PALM 
MicrobeamTM system (Carl Zeiss MicroImaging, Munich, Germany) on unstained sections. 
The micro-dissected material was catapulted into a 500μl AdhesiveCap that allows capture of 
the isolated tissue without applying any liquid into the cap prior to LCM, thus minimizing the 
risk of nuclease activity. The captured cells were stored at -80°C until DNA extraction or 
processed immediately for RNA.  
 
 
DNA extraction 
 DNA from the micro-dissected tissue and bronchial brushing samples was extracted 
using QIAGEN’s QIAmp DNA Mini and Micro kits, respectively (Crawley, UK). Soluble carrier 
RNA was used to increase tissue DNA yield. Concentration was measured using the Qubit® 
dsDNA High-Sensitivity assay and Qubit® 2.0 Fluorometer (Life Technologies, Paisley, UK). 
Nucleic acid quality and purity was estimated based on the A260/280 absorbance ratio readings 
using the NanoDrop-8000 UV-spectrophotometer (Thermo Scientific, Hertfordshire, UK). Only 
samples with an A260/280 ratio of 1.7-1.9 were included in the study. 
 
RNA extraction 
 RNA was extracted using the High Pure FFPE RNA Kit (Roche Applied Science, West 
Sussex, UK) according to manufacturer’s protocol. Quantification was carried out using the 
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Quant-iT RNA assay kit and the Qubit® 2.0 fluorometer (Life Technologies, Paisley, UK). RNA 
integrity was analyzed using a BioAnalyzer 2100 (Agilent, Stockport, UK). 
 
Bisulfite conversion 
 For each sample undergoing methylation profiling, 200 ng of DNA were bisulfite 
converted using the EZ DNA methylation kit (Zymo Research Corp., Orange, CA, USA) 
according to the manufacturer’s modified protocol for Illumina’s Infinium 450K assay. This 
protocol incorporates a cyclic denaturation step to improve the conversion efficiency3. The 10 
μl final conversion reaction was concentrated down to 4 μl with a vacufuge plus vacuum 
concentrator (Eppendorf AG, Hamburg, Germany) and sent to UCL’s Genomics Core Facility 
for hybridization on the 450K BeadArray according to Illumina’s Infinium HD protocol (Illumina 
Inc., San Diego, CA, USA) as previously described.4  
 
Infinium HumanMethylation450K raw data extraction and pre-processing 
 Illumina’s iScan fluorescent system was used to scan and image the arrays. DNA 
methylation data were extracted as raw intensity signals without any prior background 
subtraction or data normalization and were stored as IDAT files.  
CpG-specific methylation levels (β-values; continuous value ranging from 0 to 1) for 
each sample were calculated as the ratio of the fluorescent signal intensity of the methylated 
(M) and unmethylated (U) alleles according to the following formula: 
 
 
 
All subsequent raw β-value pre-processing, normalisation and down-stream analysis 
was performed using the Chip Analysis Methylation Pipeline (ChAMP) Bioconductor package 
with default settings.5  
b =
intensity of methylated allele (M)
intensity of [unmethylated (U) + methylated (M) allele] +100
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Analysis of differentially variable positions (DVP) was performed using iEVORA6. Beta 
values from ChAMP were used as input to iEVORA following normalization and batch 
correction. 
 
Genome-wide gene expression array  
The extracted FFPE RNA used to generate the gene expression profiles on the 
discovery set was sent to UCL’s Genomics Core Facility for hybridization on the Human 
Whole-Genome DASL (cDNA-mediated Annealing, Selection, extension and Ligation) 
beadarrays according to Illumina’s protocol (Illumina Inc., San Diego, CA, USA).  
The extracted FFPE RNA used to generate the gene expression profiles on the 
validation set was sent to UK Bioinformatics Limited for hybridization on the Clariom™ D 
Transcriptome Human Pico Assay 2.0 according to Affymetrix’s protocol (Thermo Fisher 
Scientific Waltham, MA, USA).  
 
Principal Component Analysis (PCA) 
 In order to identify any potential factors of variability affecting sample/group segregation, 
we applied principal component analysis on all probes passing filters defined above 
(implemented in the prcomp method of the R stats package). Technical and biological variation 
was investigated for batch arrays, smoking (pack-years), age at initial diagnosis, gender and 
previous lung cancer history. The ability of these features to predict the first principal 
component was quantified using ANOVA analysis, implemented in the R aov method. p-values 
quoted are derived from this method. 
 
Gene expression analysis 
 Raw gene expression data were expressed as log2 ratios of fluorescence intensities of 
the experimental samples. Quantile normalization was applied to Illumina data, using Illumina 
GenomeStudio Gene Expression Module v1.0 software. For Affymetrix data, RMA 
normalization was applied as defined in the affy Bioconductor package. For analyses utilizing 
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both data sets, only genes represented on both arrays were included and ComBat7 was used 
to adjust for batch effects. 
 Differential expression analysis was performed using the limma8 Bioconductor package. 
Raw p-values were adjusted by the Benjamini-Hochberg procedure to give a FDR.9 A 
significance threshold of FDR < 0.01 was used to select differentially expressed genes. Cluster 
analysis and visualization was performed using the pheatmap10 Bioconductor package.  
 
Real Time PCR Validation  
For microarray validation, total RNA from the 33 pre-invasive LUSC lesions undergoing 
Illumina gene expression profiling was reverse transcribed using qScriptTM cDNA Super-Mix 
(Quanta Biosciences, Lutterworth, UK) according to the manufacturer’s protocol. Real-time 
quantitative PCR was carried out in eight genes using the SYBR-green master mix (Applied 
BioSystems, Bleiswijk, Netherlands) in an Eppendorf real-time PCR Machine (Eppendorf, 
Stevenage, UK). Findings were validated using quantitative PCR (qPCR) for four up-regulated 
(GAGE5, GPNMB, MMP12 and STC2) and four down-regulated (SPDEF, LMO7, OBSCN and 
MT1E) genes. Gene-specific primers were designed inside or nearby the microarray sequence 
targeted, using Primer Express Software v2.0 (Thermo Fisher Scientific). Relative gene 
expression was quantified using the threshold cycle (Ct) method and normalized to the amount 
of CTBL and CEP250, which met the criteria of less variation between samples and compatible 
expression level with the studied genes. Each sample was tested in triplicate and a sample 
without template was included in each run as a negative control. Correlations between 
microarrays and real time PCR data were measured using the Pearson coefficient. From 
microarray and real time PCR data, we calculated the progressive/regressive ratio for each 
gene expression. All eight genes tested were significant in our differential microarray analysis 
with FDR < 0.05. A high degree of correlation (r=0.982) was observed between qPCR and 
array data. 
 
Predictive modelling 
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 For methylation, gene expression and copy number data we applied Prediction Analysis 
of Microarrays (PAM)11 to predict whether a sample was progressive or regressive based on 
its molecular profile. The Bioconductor pamr package was used. In all presented analyses we 
select a threshold which minimizes the number of data inputs required whilst maintaining the 
minimum possible number of classification errors. 
 PAM calculates the probability of each sample being progressive. We describe this value 
as a ‘Progression Score’. ROC analytics were performed on these progression scores to 
determine their value as a diagnostic test, using the pROC12 and PRROC13 Bioconductor 
packages. 
 For methylation and gene expression data a predictive model was trained on the training 
set and subsequently applied to an independent validation set. Regressive and control 
samples were grouped together for the methylation data analysis. ROC analytics were 
performed only on the validation set. Internal cross-validation was used for methylation-
derived copy number data due to smaller sample size (control samples are used as a baseline 
to calculate copy number, therefore are excluded from predictive analysis).   
 When multiple lesions from one patient were included in an analysis, these were treated 
as independent events as they were always taken from different sites in the lung. The outcome 
of a lesion (whether it progressed or regressed) was determined on a per-lesion basis; the 
lesion was assigned to the progressive group only if cancer developed at the same site in the 
lung, and to the regressive group only if normal or low-grade dysplasia was obtained from the 
same site in the lung. 
 In some cases different technologies were used, for example our gene expression 
discovery set used Illumina microarrays whereas our validation set used Affymetrix. In such 
instances, both data sets were reduced to the subset of genes covered by probes in both 
platforms prior to creating a predictive model. The ComBat method from the sva Bioconductor 
package was used to correct for batch effects between the different platforms. In the case of 
RNAseq data, we used the voom transformation defined in the limma Bioconductor package 
to derive data comparable to expression data prior to batch correction with ComBat. 
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 A second predictive model based on methylation probe variation was also developed. 
For a given sample we defined Methylation Heterogeneity Index (MHI) by counting all probes 
with beta values between 0.26 and 0.88. These thresholds were optimized by calculating MHI 
for a range of different threshold values, and choosing those with the highest AUC for 
progressive vs regressive in our discovery cohort. We used ROC analytics to assess this 
model as a predictor of TCGA cancer vs control samples, and of progressive vs regressive 
samples in our validation cohort. We demonstrate in the main text that applying this method 
to a random sample of 2,000 probes performs similarly to using the entire array. We ran 
simulations using different sample sizes and found that performance with n=2000 was similar 
to that of the entire array. To investigate potential confounding variables we use binomial 
logistic regression, implemented in the R glm method, to assess whether outcome 
(progression/regression) could be predicted by MHI, smoking status, COPD, previous history 
of lung cancer, age or gender. Control samples derived from brushings were excluded from 
these analyses. 
 
Copy number variation analysis 
 For samples with whole-genome sequencing available we used ASCAT14 to derive local 
copy number estimates as described below. To increase our sample size for comparative 
analyses, Copy number variation (CNV) data were obtained from non-normalised methylated 
and unmethylated signal intensities of probes in the 450K array as previously described15 
using the ChAMP Bioconductor package with default settings. Copy number (CN) profiles for 
progressive and regressive cases were obtained using the control cases for baseline 
normalisation. A previously defined threshold of ±0.3 was used for the identification of single 
CNV. Probes associated with highly polymorphic regions (e.g. major histocompatibility 
complex) were removed from the analysis. The analysis generated group CN frequency plots 
and CN profiles for each sample. For samples with both methylation and sequencing data 
available we observed good correlation between copy numbers derived from the two different 
methods (data not shown). 
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 For comparison with previous results, the ChAMP pipeline was then modified to return 
CNV values per-probe. Probe locations were matched to cytogenetic bands using the 
Ensembl GRCh37 assembly, obtained from 
http://grch37.rest.ensembl.org/info/assembly/homo_sapiens?content-
type=application/json&bands=1, such that copy number variation could be assessed by 
cytogenetic band. The mean CNV value for each of 778 cytogenetic bands was calculated for 
each of our 54 samples. Limma analysis was used to identify bands that differed significantly 
between progressive and regressive samples with BH-adjusted p-value < 0.05. Predictive 
modelling was performed using PAM to find bands predictive of progression, using the same 
method as for gene expression data. Due to the low number of regressive samples, an internal 
cross-validation method was used rather than separate discovery and validation sets. 
 Following identification of predictive cytogenetic bands, PAM modelling was repeated 
with the dataset limited to only those bands identified by van Boerdonk et al: 3q26.2−29, 
3p26.3−p11.1 and 6p25.3−p24.3.16,17 This model was also accurate. 
 Finally, we applied our model to the validation data set of 24 regressive and 12 
progressive samples used by van Boerdonk et al (GEO accession number GSE45287). These 
data were measured using a different microarray platform (arrayCGH). We assigned each 
probe to a cytogenetic band, and took the mean values to create a matrix of expression values 
by band. Our model was applied to the subset of chromosomal bands present in both data 
sets (760 of 778 bands). ComBat was used for batch correction between the two platforms. 
Our model correctly predicted 24/24 regressive samples and 9/12 progressive samples, 
replicating the results of van Boerdonk et al. 
 
External validation using TCGA 
 Lung cancer methylation datasets publically available through The Cancer Genome 
Atlas (TCGA) were downloaded using GenomicDataCommons download tools18. We obtained 
the normalized β-values of 370 LUSC samples and 42 normal controls. ComBat was used to 
correct for batch effects between our data and TCGA data. These data were used as an 
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external validation set to test our predictive models, and as input for our differential analysis 
of progression drivers from control through CIS to cancer. 
 Gene-expression microarray data sets comparable to our data were not publically 
available. RNAseq data was available from TCGA for 502 LUSC samples and 49 control 
samples. We applied a voom transformation19 to these data, which uses normalized log-
counts-per-million as an approximation for expression values, and hence allows comparison 
of RNAseq data with our gene expression pipeline. ComBat was used to correct for batch 
effects. The predictive model generated using PAM on our gene expression microarray data 
was applied to voom-transformed RNAseq data from TCGA and shown to be predictive (Fig. 
4C). We therefore demonstrate the applicability of our model to this fully independent data set. 
These data were again used as input to our differential analysis of progression drivers. 
 
Pathway analysis 
 For gene expression data, the GAGE Bioconductor package20 was used with KEGG 
gene sets21-23 to identify pathways associated with genes differentially expressed in our 
analysis of progression to cancer (BH-adjusted p-value <0.01). In addition to these pathways 
we use the CIN70 signature defined by Carter et al.24 to assess for a chromosomal instability 
signal. We also use a subset of the CIN70 genes with cell-cycle associated genes25 removed 
to ensure that our signal is genuinely CIN-related, rather than a measure of proliferation. 
 Methylation data was analysed in the same way, using beta values as input to GAGE. 
In cases where there are multiple methylation probes for a single gene we use the mean beta 
value over that gene as input to pathway analysis. We acknowledge that using mean signal 
may be insensitive to single-probe methylation changes, however given the scale of changes 
observed we believe it will identify areas of large methylation change. 
 
Genomic sequencing 
We created genome-wide shotgun libraries (insert size 331-367 bp) from native DNA 
using the Agilent Technologies Custom SureSelect Library Prep Kit library (cat no. 930075). 
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150 bp paired-end sequence data were generated using the Illumina HiSeq X Ten system. 
Sequenced data were realigned to the human genome (NCBI build 37) using BWA-MEM. 
Unmapped reads and PCR duplicates were removed. A minimum sequencing depth of 40x 
was required. 
 
Somatic mutation calling and annotation 
Single base somatic substitutions were identified by our in-house algorithm Cancer 
Variants through Expectation Maximisation (CaVEMan: 
https://github.com/cancerit/CaVEMan)26. This algorithm compares the sequence data from 
each tumour sample to its matched normal and calculates a mutation probability at each locus. 
This calculation incorporates information from aberrant cell fraction and copy number 
estimates from the Allele-Specific Copy number Analysis of Tumours (ASCAT) algorithm 
(https://www.crick.ac.uk/peter-van-loo/software/ASCAT).14,27 Additional post-processing as 
described previously28 was implemented. Any putative driver mutations were visually 
inspected with Jbrowse.29 For every substitution that passed all filters in at least one sample, 
we counted the number of wild-type and mutant reads at the same position in all other samples 
from the same patient to see if that mutation was also present in related samples but had not 
been called.  
 
Somatic small insertions and deletions 
These were identified using our in-house algorithm Pindel.30,31 As with substitutions, all 
putative driver mutations were visualised with Jbrowse. 
 
Somatic structural variant detection” 
Abnormally paired read pairs were grouped using an in-house tool, “Brass”.32 Read 
groups overlapping genomic repeats, reads from the matched normal, or from a panel of 
unmatched normals were ignored. Read pair clusters were then filtered by read remapping. 
Read pair clusters with >50% of the reads mapping to microbial sequences were removed. 
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Finally, candidate SV breakpoints were matched to copy number breakpoints as defined by 
ASCAT within 10 kb. Candidate SVs that were not associated with copy number segmentation 
breakpoints and with a copy number change of at least 0.3 were removed.  All putative driver 
rearrangements were visually inspected using IGV.33,34 
 
Somatic copy number events, ploidy, and stromal contamination 
Copy number changes were derived from whole-genome sequencing data using the 
ASCAT algorithm. This algorithm compares the relative representation of heterozygous SNPs 
and the total read depth at these positions to estimate the aberrant cell fraction and ploidy for 
each sample, and then to determine allele-specific copy number.  
 
Weighted Genome Integrity Index 
 To estimate the overall chromosomal instability of a sample, we use the Weighted 
Genome Integrity Index (wGII) score35. This is calculated by measuring the percentage of the 
genome which is abnormal, corrected such that each chromosome is equally weighted.  
 
Mutation annotation 
Lung cancer driver genes were selected from the COSMIC Cancer Gene Census (CGC) 
v85 (cancer.sanger.ac.uk)36. CGC data was downloaded on 20th June 2018. Genes annotated 
in the CGC as potential drivers in lung cancer or NSCLC were included. Those specific to 
adenocarcinoma were excluded as our samples are precursors to squamous cancers. Genes 
identified in two large studies of squamous cell cancer, and some additional genes based on 
expert curation of the literature (ARID1A, AKT2, FAT1, PTPRB) were included if they were 
present in the CGC – even if they were not annotated explicitly as implicated in lung cancer. 
Both Tier 1 and Tier 2 genes were included. A total of 96 genes were selected as putative lung 
squamous cell carcinoma drivers (Supplementary Table 4). 
 Mutations affecting these putative driver genes were annotated as driver mutations if 
they passed the following filters: 
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 The mutation type (e.g. missense, frameshift, amplification) must have been validated 
in the CGC for the affected gene. 
 For genes annotated as tumour suppressors, mutations determined to have High or 
Moderate impact using Ensembl’s Variant Effect Predictor37 were classed as driver 
mutations. 
 For genes annotated as oncogenes, we checked the specific mutation against COSMIC 
mutation data for lung carcinomas. If the specific mutation occurred 3 or more times in 
this dataset it was classed as a driver mutation. 
 For genes annotated as fusion proteins, translocations with a translocation partner gene 
matching validated tranlocation partner genes in the CGC were classed as driver 
events. 
 Copy number amplifications and deletions were all classed as driver events if 
amplifications/deletions in the affected gene have been previously validated in the 
CGC. We included homozygous deletions of tumour suppressor genes and 
amplifications to more than double the sample ploidy for oncogenes. 
 
 Driver mutation discovery was also attempted using dndscv38. This was 
underpowered, however, and only yielded TP53 and CDKN2A as genes under positive 
selection. This package was also used to estimate the global dNdS for both progressive and 
regressive lesions. 
 
Subclonality analysis 
The number of subclones contributing to a sample and their relative contribution was 
estimated by using a modified version of the sciClone Bioconductor package39. sciClone uses 
a Bayesian method to allocate mutations to clusters based on their variant allele frequency 
(VAF). By default, sciClone only considers regions that are copy number neutral and LOH-
free. Given the significant aneuploidy in our data set we overcame this limitation by clustering 
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on cancer cell fraction (CCF) rather than VAF. Briefly, cancer cell fraction represents the 
fraction of cancer cells in which a given mutation is present, therefore clonal mutations will 
have CCF=1. Following the method of McGranahan et al.40, we estimated the CCF for each 
mutation with a 95% confidence interval. Mutations for which 1 lay within this confidence 
interval were labelled as ‘clonal’, other mutations as ‘subclonal’. 
CCF values for each mutation were then used as input to sciClone in place of VAF 
values to quantify clusters present (divided by 2 such that clonal mutations have a value of 
0.5). As CCF corrects for local copy number, all regions were assumed to have copy number 
of 2, allowing sciClone to group mutations based only on their CCF estimates. A minimum 
tumour sequencing depth of 10 was required for each mutation. 
 Where more than one sample from a given patient was available, both one dimensional 
and multi-dimensional clustering were performed. Results from one dimensional clustering 
were used in the comparison of numbers of clones and proportion of clonal mutations between 
progressive and regressive lesions, in order to provide as fair a comparison as possible. 
 
Extraction of mutational signatures  
To obtain an approximate estimate of the contribution of different known mutational 
signatures to each sample, we used the MutationalPatterns Bioconductor package41. As a 
reference set of mutational signatures, we used a table with the relative frequency of each of 
the 96 trinucleotide substitutions across 30 known mutation signatures,42,43 available through 
the COSMIC website (http://cancer.sanger.ac.uk/cosmic/signatures). 
 After a first run which indicated the most likely contribution of each signature, it seemed 
that the majority of substitutions were contributed by signatures 1, 2, 4, 5, and 13, which have 
been described to be the strongest signatures in lung squamous cell cancer.44 Some 
contribution was identified from signatures 16, 8, 18 and 3 in our initial analysis; however, in 
this context it is likely that these represent overfitting given that signature 16 is similar to 
signature 5, and signatures 8, 18 and 3 are similar to signature 4. We therefore ran the 
algorithm a second time, this time only using a 5x96 matrix of mutational signatures 1, 2, 4, 5 
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and 13. All mutations were thus forced to belong to one of these five mutational signatures. 
 For a comparison of the clonal vs subclonal mutational processes in each sample, 
substitutions were annotated as clonal or subclonal based on CCF as described above. These 
were then run through the MutationalPatterns package. 
 
Comparison of mutational burden and signatures with other cancer types 
Signatures of mutations in our CIS dataset were compared with mutational signatures 
found in lung squamous cell cancer.  Raw whole-exome sequencing data for this cancer type 
was downloaded from TCGA, and run through our substitution-calling algorithm CAVEMaN as 
described above. We then looked at the total number of subsitutions called, and estimated the 
contribution of each mutational signature using the methods described above. Only coding 
regions of the CIS whole-genome sequencing data were compared to these exomes. 
 
Estimation of telomere lengths 
Telomere lengths were estimated using telomerecat45, and were compared in 
progressive and regressive groups. Telomerecat is a de novo method for the estimation of 
telomere length (TL) from whole-genome sequencing samples. The algorithm works by 
comparing the ratio of full telomere reads to reads on the boundary between telomere and 
subtelomere. This ratio is transformed to a measure of length by taking into account the 
fragment length distribution. Telomerecat also corrects for error in sequencing reads by 
modeling the observed distribution of phred scores associated with mismatches in the 
telomere sequence. Samples were analysed in two groups corresponding to two separate 
sequencing batches, as per the telomerecat documentation. 
 
Data Availability Statement 
 Whole-genome sequencing data have been deposited at the European Genome 
Phenome Archive (https://www.ebi.ac.uk/ega/ at the EBI) with accession number 
EGAD00001003883. All gene expression and methylation microarray data reported in this 
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study have been deposited in the National Center for Biotechnology Information Gene 
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) public repository, and they are 
accessible through GEO accession number GSE108124. 
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